Last updated: February 19, 2026
Who Are the Main Suppliers of Bedaquiline Fumarate?
Bedaquiline fumarate is a targeted antimicrobial primarily used to treat multidrug-resistant tuberculosis (MDR-TB). It is marketed under the brand name Sirturo by Johnson & Johnson. The drug's supply chain involves a limited group of manufacturers due to complex synthesis processes and stringent quality controls.
Primary Commercial Supplier
| Supplier |
Country |
Manufacturing Facility |
Market Presence |
Notes |
| Johnson & Johnson (Janssen Pharmaceuticals) |
United States |
Multiple (including U.S., Europe, India) |
Exclusive global supplier |
Developed and first marketed bedaquiline, owns patent rights, responsible for global distribution. |
Note: Johnson & Johnson holds the original patent and marketing rights for bedaquiline, making it the sole producer for its branded formulation.
Generic Manufacturers (Janssen’s Patent Status & Licensing)
Following patent expiration or through license agreements, several generic manufacturers produce bedaquiline fumarate.
| Manufacturer |
Country |
Licensing Status |
Key Markets |
Notes |
| Dr. Reddy's |
India |
Licensed |
India, some developing countries |
Licensed by Johnson & Johnson, approved by Indian authorities. |
| Mylan |
India, Egypt |
Licensed |
India, Egypt, other low-income markets |
Licensed by Johnson & Johnson, approved by respective regulators. |
| Strides Pharma |
India |
Licensed |
India |
Licensed, approved for marketing in India. |
| Zheijiang Hisun |
China |
Not licensed |
China |
Produces in China, not licensed globally, potential importation barriers. |
Note: The licensing agreements vary by country; some generics are limited to specific regions due to patents and regulatory policies.
Regulatory Approvals and Manufacturing Sites
- Johnson & Johnson operates manufacturing plants in the United States, Ireland, and India, adhering to Good Manufacturing Practice standards.
- Generic manufacturers often produce under WHO prequalification or national approvals, with facilities in India, China, and Egypt.
Alternatives and Importation Strategies
In regions lacking licensed supply, countries may import generic versions where patent laws permit or engage in compulsory licensing under TRIPS flexibilities to enhance access.
Market Dynamics and Supply Constraints
- Patent protection for bedaquiline expired in some jurisdictions (e.g., India in 2022), opening markets for generics.
- Patent extensions or litigation may delay generic entry in certain regions.
- Supply depends on manufacturing capacity, regulatory approval, and distribution logistics.
Summary Table of Key Points
| Aspect |
Details |
| First marketed by |
Johnson & Johnson (Janssen) |
| Patent expiration |
Varies by jurisdiction (e.g., India 2022) |
| Primary generic suppliers |
Dr. Reddy's, Mylan, Strides Pharma, Zheijiang Hisun |
| Licensing |
Generally licensed from Janssen in developing markets |
| Market restrictions |
Patent protections, licensing agreements, regulatory approvals |
Key Takeaways
- Johnson & Johnson remains the sole supplier of branded bedaquiline globally.
- Multiple licensed generic manufacturers operate primarily in India, Egypt, and China.
- Patent expirations in certain regions facilitate broader generic manufacturing.
- Supply chain depends on manufacturing capacity, regulatory status, and licensing agreements.
- Access in low-income countries hinges on licensing or legal measures such as compulsory licensing.
FAQs
Q: How is the supply of bedaquiline affecting access in low-income countries?
A: Patent protections and licensing agreements restrict generic production; however, patent expirations and voluntary licenses improve access.
Q: Which countries are licensed to produce generics?
A: India, Egypt, and China host licensed generic manufacturing, primarily through Dr. Reddy's, Mylan, and Zheijiang Hisun.
Q: Are there approved generic versions globally?
A: Approved generics exist mainly in India and some other low- and middle-income countries under licensing agreements; other markets may face regulatory or patent barriers.
Q: How does patent status influence the supply chain?
A: Patent protections restrict generic manufacturing; patent expirations in key markets enable increased competition and supply.
Q: What factors could disrupt supply in the future?
A: Patent enforcement, manufacturing capacity issues, regulatory delays, or legal disputes could impact availability.
References
[1] World Health Organization. (2020). Technical Report on Tuberculosis. WHO.
[2] Food and Drug Administration. (2021). Sirturo (bedaquiline) approval information. FDA.
[3] Johnson & Johnson. (2022). Sirturo patent and licensing policy updates. official statement.
[4] GlobalData. (2022). Pharmaceutical Market Report: Bedaquiline market analysis.
[5] Indian Patent Office. (2022). Patent status review for bedaquiline fumarate. Govt. of India.
